Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel
24 Maio 2023 - 9:30AM
Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the
“Company”), a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines, today announced the appointment of
Megan Yung as Chief Strategy Officer and General Counsel. Ms. Yung
will work with Eterna’s senior leadership and the Board of
Directors to develop and advance the Company’s corporate strategy.
Ms. Yung will also oversee the company’s legal activities,
including licensing and intellectual property matters.
“Megan is an experienced biotech strategist with
a proven track record of building value for companies through
high-value strategic transactions and we are thrilled to welcome
her to Eterna’s leadership team,” said Matt Angel, Ph.D., Chief
Executive Officer and President of Eterna. “Her deep experience
operating at the intersection of science, corporate strategy and
intellectual property will benefit Eterna, our current and
potential partners, and our shareholders through her focus on
advancing the company's business strategies, as we continue
supporting the development of next-generation mRNA-based
therapeutic products.”
Ms. Yung added, “I look forward to working
closely with the Eterna leadership team and Board to advance the
company’s strategy while maintaining capital efficiency, as Eterna
enters a new chapter following its recent acquisition of Exacis
Biotherapeutics. RNA-based therapeutics have continued to garner
significant scientific and investor interest and Eterna is
well-primed to create value through new strategic
collaborations.”
Ms. Yung holds a J.D. from The George Washington
University Law School and joins Eterna from SQZ Biotechnologies,
where she served as Deputy General Counsel and Vice President, Head
of Intellectual Property, and helped oversee matters of
intellectual property, regulatory compliance, public company
reporting, business development activities and negotiations, and
government affairs. Prior to SQZ, Ms. Yung held in-house counsel
positions where she served as a key member of the deal teams
involving strategic bet-the-company, venture capital, and private
equity financing deals, and as chief counsel on all litigation,
including intellectual property, employment matters, and class
action law suits. These successful activities built on the
expertise she cultivated as an intellectual property attorney at
Quinn Emanuel Urquhart & Sullivan, Mintz Levin Cohn Ferris
Glovksy and Popeo, and Foley & Lardner, where she represented
and advised biotech and pharmaceutical companies in patent
litigation, prosecution, and IP strategy.
About Eterna TherapeuticsEterna
Therapeutics is a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines. Eterna has in-licensed a portfolio
of over 130 patents covering key mRNA cell engineering
technologies, including technologies for mRNA cell reprogramming,
mRNA gene editing, the NoveSlice™ and UltraSlice™ gene-editing
proteins, and the ToRNAdo™ mRNA delivery system from Factor
Bioscience. NoveSlice™, UltraSlice™, and ToRNAdo™ are trademarks of
Factor Bioscience. For more information, please visit
www.eternatx.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are intended to be covered by the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are any statements that are not
statements of historical fact and may be identified by terminology
such as “believe,” “could,” “estimate,” “anticipate,” “expect,”
“plan,” “possible,” “potential,” “project,” “will” or other similar
words and the negatives of such words. Forward-looking statements
are based on current beliefs and assumptions that are subject to
risks and uncertainties and are not guarantees of future
performance. Actual results could differ materially from those
stated or implied in any forward-looking statement as a result of
various factors, including, but not limited to, uncertainties
related to: (i) the evolution of Eterna’s business model into a
platform company focused on mRNA, iPS cell and gene editing
technologies; (ii) Eterna’s ability to successfully,
cost-effectively and efficiently develop its technology and
products; (iii) Eterna’s ability to successfully commence clinical
trials of any products on a timely basis or at all; (iv) Eterna’s
ability to successfully fund and manage the growth of its
development activities; and (v) Eterna ’s ability to obtain
regulatory approvals of its products for commercialization. You
should not rely upon forward-looking statements as predictions of
future events. The forward-looking statements made in this
communication speak only as of the date on which they were made,
and Eterna does not undertake any obligation to update the
forward-looking statements contained herein to reflect events that
occur or circumstances that exist after the date hereof, except as
required by applicable law. Factors that may cause Eterna’s actual
results to differ from those expressed or implied in
forward-looking statements contained in this press release are more
fully disclosed in Eterna’s periodic public filings with the U.S.
Securities and Exchange Commission, particularly under the heading
“Risk Factors” in Eterna’s Annual Report on Form 10-K for the year
ended December 31, 2022, as well as under similar headings in
Eterna’s subsequently filed Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K.
Eterna Therapeutics
Investorsinvestors@eternatx.com
Eterna Therapeutics
MediaEternaPR@westwicke.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c19b7580-ac17-496d-98aa-85bdeb59e693
Eterna Therapeutics (NASDAQ:ERNA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Eterna Therapeutics (NASDAQ:ERNA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024